세계의 첨단 암 진단약 시장 규모, 점유율, 동향 분석 : 검사별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Advanced Cancer Diagnostics Market Summary

The global advanced cancer diagnostics market size was estimated at USD 58.30 billion in 2024 and is expected to reach USD 127.07 billion by 2033, expanding at a CAGR of 9.05% from 2025 to 2033. The market is driven by several strong factors. Rising global cancer incidence continues to expand demand for early and precise detection, while patient survival benefits from timely diagnosis are pushing adoption of genomic, molecular, and imaging-based tools.

Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics are accelerating precision oncology, enabling more personalized and effective treatment. Cost-efficiency also acts as a driver, with case studies showing significant healthcare savings when diagnostics reduce late-stage treatments and adverse drug reactions. Alongside this, expanding reimbursement frameworks and large-scale initiatives like ECII are improving access and adoption.

The market dynamics for advanced cancer diagnostics are being shaped by rapid technological progress, evolving policy frameworks, and shifting healthcare priorities. Historically, cancer diagnosis and treatment were guided primarily by tumor location and stage, but the advent of advanced diagnostics has changed this paradigm. These new tools provide granular insights into the molecular, genetic, and biological underpinnings of cancer, making precision medicine a tangible reality. By enabling earlier and more accurate diagnosis, advanced diagnostics reduce the chances of missed or incorrect diagnoses and open the door to more personalized treatment selection. This precision minimizes patient exposure to ineffective therapies and their associated side effects, while also supporting real-time monitoring of treatment effectiveness.

The potential benefits extend beyond patient outcomes to health system efficiency. Health systems that integrate advanced diagnostics could see significant cost savings by reducing the need for ineffective treatments and minimizing hospitalizations from adverse drug reactions. One case study from Ireland illustrates this impact: testing colorectal cancer patients for specific genetic variations generated savings of more than USD 55 million per patient, primarily by avoiding severe side effects that would have required hospital care. Similarly, early detection yields strong cost advantages. In breast cancer, early-stage diagnosis has been shown to reduce medical costs by nearly 50%, equivalent to hundreds of millions of USD per patient cohort when compared with late-stage disease.

Technology adoption can also save resources within the health system itself. A U.S. case study demonstrated that the use of digital pathology at an academic medical center delivered savings of USD 1.3 million over five years, while simultaneously improving accuracy and cutting diagnostic review times by more than 30%. Artificial intelligence integration thus emerges as both a clinical and economic catalyst, reshaping workflow efficiency and lowering error rates.

At the same time, barriers to adoption remain significant. Advanced diagnostics are still largely restricted to research facilities or specialist hospitals, meaning equitable access across wider health systems is limited. Regulatory and reimbursement challenges are particularly acute. Traditional frameworks are not well-suited to adaptive technologies like AI-based diagnostics, which continue to evolve after approval. The EU's TEF-Health initiative, launched in 2023 with funding of nearly USD 66 million, serves as a case study of regulatory innovation, providing a sandbox for real-world testing of new approaches under supervision. Yet, delays tied to the rollout of the In Vitro Diagnostic Medical Devices Regulation (IVDR) highlight the risks of bottlenecks. Analysts estimate that up to 27,400 cancer patients may face delays in clinical trial access, translating into indirect economic and treatment costs of several hundred million USD.

Alternative funding models also reveal the scale of potential benefits. Australia's reimbursement scheme for hepatitis C, introduced in 2016 with funding of USD 792 million, stands as a landmark case study. The program secured projected productivity gains worth USD 4.1 billion and a net economic benefit of USD 3.8 billion by 2030. Applying such models to oncology diagnostics could unlock sustainable access and uptake, particularly in areas like liquid biopsy and genetic testing.

Infrastructure remains another challenge. In many European health systems, biopsy samples still travel across multiple facilities before reaching final analysis, delaying care. Whole-genome sequencing at diagnosis could streamline this process, but requires large-scale investments. Data-sharing barriers also remain critical. The European Cancer Imaging Initiative (ECII), launched in 2023, provides a case study of collaborative infrastructure, establishing a continent-wide platform for cancer image exchange worth more than USD 55 million. Such efforts aim to break down silos, broaden datasets, and accelerate diagnostic innovation.

On the technology front, Liquid biopsy, as demonstrated in a study from England, detected relapse three to five months earlier than scans and saved USD 72 million for every 100 brain tumor patients tested. Similar advances are being seen with total-body PET imaging, which improves sensitivity 40-fold while lowering scan time and radiation dose, and with multiparametric MRI, which has already spared more than 25% of suspected prostate cancer patients from invasive biopsies, amounting to system-level savings in the hundreds of millions of USD annually.

Artificial intelligence continues to unify these advances. A case study in breast cancer demonstrated AI's ability to detect high HER2 expression and improve patient stratification, ensuring better treatment matching and delivering system-level efficiencies worth tens of millions of USD per year. Computational pathology further accelerates analysis by up to 50% compared to manual reviews, while maintaining or improving accuracy.

The advanced cancer diagnostics are moving from promise to practice, with case studies across Ireland, the U.S., Australia, and England proving their clinical and economic impact. Yet, gaps in regulation, funding, infrastructure, and equity remain. These dynamics suggest a future defined by both opportunities and challenges. If policymakers and industry leaders act in tandem adapting regulatory frameworks, piloting innovative funding models, investing in digital and diagnostic infrastructure, and ensuring equitable implementation advanced diagnostics will not only transform cancer care but also reshape healthcare economics across the next decade.

Global Advanced Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For the purpose of this report, Grand View Research has segmented the global advanced cancer diagnostics market report on the basis of test, end use, and region:

• Test Outlook (Revenue, USD Billion, 2021 - 2033)
• Tumor Marker Tests
• Fine Needle Aspiration Cytology (FNAC) & Biopsy
• Imaging-Based Diagnostics
• Bone Marrow Aspiration & Biopsy
• Immunohistochemistry (IHC) & Molecular Testing
• Genetic Testing for Cancer
• Liquid Biopsy
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals & Cancer Specialty Centers
• Diagnostic Laboratories (Independent & Reference Labs)
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Market Definitions
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Cancer Type and End Use Snapshot
• 2.3. Technique and End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Business Environment Analysis
  • 3.4.1. PESTLE Analysis
  • 3.4.2. Porter's Five Forces Analysis
• 3.5. COVID-19 Impact Analysis

Chapter 4. Test Business Analysis

• 4.1. Advanced Cancer Diagnostics Market: Test Movement Analysis, 2024 & 2033
• 4.2. Tumor Marker Tests
  • 4.2.1. Tumor Marker Tests Market, 2021 - 2033 (USD Billion)
• 4.3. Fine Needle Aspiration Cytology (FNAC) & Biopsy
  • 4.3.1. Fine Needle Aspiration Cytology (FNAC) & Biopsy market, 2021 - 2033 (USD Billion)
• 4.4. Imaging-Based Diagnostics
  • 4.4.1. Imaging-Based Diagnostics market, 2021 - 2033 (USD Billion)
• 4.5. Bone Marrow Aspiration & Biopsy
  • 4.5.1. Bone Marrow Aspiration & Biopsy market, 2021 - 2033 (USD Billion)
• 4.6. Immunohistochemistry (IHC) & Molecular Testing
  • 4.6.1. Immunohistochemistry (IHC) & Molecular Testing market, 2021 - 2033 (USD Billion)
• 4.7. Genetic Testing
  • 4.7.1. Genetic Testing Market, 2021 - 2033 (USD Billion)
• 4.8. Liquid Biopsy
  • 4.8.1. Liquid Biopsy Market, 2021 - 2033 (USD Billion)

Chapter 5. End Use Business Analysis

• 5.1. Advanced Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033
• 5.2. Hospitals & Cancer Specialty Centers
  • 5.2.1. Hospitals & Cancer Specialty Centers Market, 2021 - 2033 (USD Billion)
• 5.3. Diagnostic Laboratories
  • 5.3.1. Diagnostic Laboratories market, 2021 - 2033 (USD Billion)
• 5.4. Research & Academic Institutes
  • 5.4.1. Research & Academic Institutes market, 2021 - 2033 (USD Billion)
• 5.5. Pharmaceutical & Biotechnology Companies
  • 5.5.1. Pharmaceutical & Biotechnology Companies market, 2021 - 2033 (USD Billion)
• 5.6. Others
  • 5.6.1. Others Institutes market, 2021 - 2033 (USD Billion)

Chapter 6. Regional Business Analysis

• 6.1. Regional Market Snapshot
• 6.2. North America
  • 6.2.1. North America Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
  • 6.2.2. U.S.
    • 6.2.2.1. U.S. Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.2.2.2. Key Country Dynamics
    • 6.2.2.3. Regulatory Framework
    • 6.2.2.4. Competitive Scenario
  • 6.2.3. Canada
    • 6.2.3.1. Canada Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.2.3.2. Key Country Dynamics
    • 6.2.3.3. Regulatory Framework
    • 6.2.3.4. Competitive Scenario
  • 6.2.4. Mexico
    • 6.2.4.1. Mexico Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.2.4.2. Key Country Dynamics
    • 6.2.4.3. Regulatory Framework
    • 6.2.4.4. Competitive Scenario
• 6.3. Europe
  • 6.3.1. Europe Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
  • 6.3.2. Germany
    • 6.3.2.1. Germany Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.2.2. Key Country Dynamics
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Competitive Scenario
  • 6.3.3. UK
    • 6.3.3.1. UK Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.3.2. Key Country Dynamics
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Competitive Scenario
  • 6.3.4. France
    • 6.3.4.1. France Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.4.2. Key Country Dynamics
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Competitive Scenario
  • 6.3.5. Italy
    • 6.3.5.1. Italy Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.5.2. Key Country Dynamics
    • 6.3.5.3. Regulatory Framework
    • 6.3.5.4. Competitive Scenario
  • 6.3.6. Spain
    • 6.3.6.1. Spain Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.6.2. Key Country Dynamics
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Competitive Scenario
  • 6.3.7. Denmark
    • 6.3.7.1. Denmark Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.7.2. Key Country Dynamics
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Competitive Scenario
  • 6.3.8. Sweden
    • 6.3.8.1. Sweden Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.8.2. Key Country Dynamics
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Competitive Scenario
  • 6.3.9. Norway
    • 6.3.9.1. Norway Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.9.2. Key Country Dynamics
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Competitive Scenario
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
  • 6.4.2. Japan
    • 6.4.2.1. Japan Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.2.2. Key Country Dynamics
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Competitive Scenario
  • 6.4.3. China
    • 6.4.3.1. China Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.3.2. Key Country Dynamics
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Competitive Scenario
  • 6.4.4. India
    • 6.4.4.1. India Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.4.2. Key Country Dynamics
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Competitive Scenario
  • 6.4.5. South Korea
    • 6.4.5.1. South Korea Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.5.2. Key Country Dynamics
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Competitive Scenario
  • 6.4.6. Australia
    • 6.4.6.1. Australia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.6.2. Key Country Dynamics
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Competitive Scenario
  • 6.4.7. Thailand
    • 6.4.7.1. Thailand Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.7.2. Key Country Dynamics
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Competitive Scenario
• 6.5. Latin America
  • 6.5.1. Latin America Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
  • 6.5.2. Key Country Dynamics
  • 6.5.3. Regulatory Framework
  • 6.5.4. Competitive Scenario
  • 6.5.5. Brazil
    • 6.5.5.1. Brazil Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.5.5.2. Key Country Dynamics
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Competitive Scenario
  • 6.5.6. Argentina
    • 6.5.6.1. Argentina Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.5.6.2. Key Country Dynamics
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Competitive Scenario
• 6.6. MEA
  • 6.6.1. MEA Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
  • 6.6.2. South Africa
    • 6.6.2.1. South Africa Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.6.2.2. Key Country Dynamics
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Competitive Scenario
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Saudi Arabia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.6.3.2. Key Country Dynamics
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Competitive Scenario
  • 6.6.4. UAE
    • 6.6.4.1. UAE Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.6.4.2. Key Country Dynamics
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Competitive Scenario
  • 6.6.5. Kuwait
    • 6.6.5.1. Kuwait Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.6.5.2. Key Country Dynamics
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Competitive Scenario

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Strategy Mapping
  • 7.2.1. Acquisition
  • 7.2.2. Collaborations
  • 7.2.3. New Platform Launches
  • 7.2.4. Others
• 7.3. Company Profiles/Listing
  • 7.3.1. Fujifilm Holdings Corporation
    • 7.3.1.1. Company Overview
    • 7.3.1.2. Financial Performance
    • 7.3.1.3. Platform Benchmarking
    • 7.3.1.4. Strategic Initiatives
  • 7.3.2. GE Healthcare
    • 7.3.2.1. Company Overview
    • 7.3.2.2. Financial Performance
    • 7.3.2.3. Platform Benchmarking
    • 7.3.2.4. Strategic Initiatives
  • 7.3.3. Siemens Healthineers
    • 7.3.3.1. Company Overview
    • 7.3.3.2. Financial Performance
    • 7.3.3.3. Platform Benchmarking
    • 7.3.3.4. Strategic Initiatives
  • 7.3.4. Philips Healthcare
    • 7.3.4.1. Company Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Platform Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Thermo Fisher Scientific
    • 7.3.5.1. Company Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Platform Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. Illumina, Inc.
    • 7.3.6.1. Company Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Platform Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Agilent Technologies
    • 7.3.7.1. Company Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Platform Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Bio-Rad Laboratories
    • 7.3.8.1. Company Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Platform Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Canon Medical Systems
    • 7.3.9.1. Company Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Platform Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Bruker Corporation
    • 7.3.10.1. Company Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Platform Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. BD
    • 7.3.11.1. Company Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Platform Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. Bio-Rad Laboratories
    • 7.3.12.1. Company Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Platform Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Myriad Genetics
    • 7.3.13.1. Company Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Platform Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Roche Diagnostics
    • 7.3.14.1. Company Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Platform Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. F. Hoffmann-La Roche Ltd.
    • 7.3.15.1. Company Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Platform Benchmarking
    • 7.3.15.4. Strategic Initiatives